Risk factors
Annexon (ANNX) risk factors
Item 1A of every Annexon, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors81 risks7 new3 dropped15 reworded
Annexon expanded its risk disclosures around international supply chain exposure, European pricing pressures, and foreign clinical trial data acceptance by the FDA. The company renamed ANX005 to tanruprubart and updated its NOL carryforward figures to $556.1 million in federal losses.
Filed Mar 30, 2026 - FY2024 10-K risk factors77 risks
Annexon depends heavily on financing its lead clinical programs ANX005 for GBS and ANX007 for dry AMD. The company faces high regulatory hurdles, international trial execution risks, and lacks internal commercial infrastructure.
Filed Mar 03, 2025